Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alexion Pharmaceuticals, Inc.    ALXN   US0153511094

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/23/2015 02/24/2015 02/25/2015 02/26/2015 02/27/2015 Date
184.14(c) 182.29(c) 184.9(c) 183.11(c) 180.11 Last
767 740 847 427 922 458 757 501 681 719 Volume
-1.01% -1.00% +1.43% -0.97% -1.64% Change
More quotes
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders.It focuses on developing products for the treatment of diseases in the... 
Sector
Pharmaceuticals
Calendar
03/02 | 02:50pmPresentation
More about the company
Surperformance© ratings of Alexion Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Chart ALEXION PHARMACEUTICALS, I
Duration : Period :
Alexion Pharmaceuticals, I Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Full-screen chart
Financials ($)
Sales 2015 2 641 M
EBIT 2015 1 317 M
Net income 2015 916 M
Finance 2015 2 858 M
Yield 2015 -
Sales 2016 3 282 M
EBIT 2016 1 732 M
Net income 2016 1 195 M
Finance 2016 4 309 M
Yield 2016 -
PER 2015 42,11
PER 2016 31,48
EV / Sales 2015 12,9x
EV / Sales 2016 9,97x
Capitalization 37 015 M
More Financials
Latest news on ALEXION PHARMACEUTICALS, I
06:31a ALEXION PHARMACEUTICALS : Joins Patient Organizations Worldwide in Support of In..
02/23 Valeant eyes smaller deals to build on Salix, Dendreon purchases
02/23 ALEXION PHARMACEUTICALS : to Present at Investor Conferences
02/23 Canada's Valeant to acquire Salix in $10.1 billion deal
02/09 ALEXION PHARMACEUTICALS : New Data from a Natural History Study in Patients with..
02/05 ALEXION PHARMACEUTICALS : to Present at the 2015 Leerink Global Healthcare Confe..
02/03 ALEXION PHARMACEUTICALS : Insights From the Pharmaceutical Space: New Research o..
02/03 ALEXION PHARMACEUTICALS : Posts Fourth Quarter and Full Year 2014 Results and Pr..
More news
Sector news Biopharmaceuticals
04:06p ZOETIS : Declares Second Quarter 2015 Dividend
01:35p BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts Biologics Licen..
12:54p MYLAN : Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi® an..
Plus d'actualités du secteur Biopharmaceuticals


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF